Co-Director, Johns Hopkins Myositis Center
Dr. Lloyd is a Professor of Neurology and Neuroscience at Johns Hopkins University specializing in degenerative diseases of the neuromuscular system including Inclusion Body Myositis (IBM) and Amyotrophic Lateral Sclerosis (ALS). After completing medicine internship and neurology residency at Johns Hopkins Hospital, he performed a postdoctoral fellowship in neuromuscular disorders to gain clinical expertise in muscle and motor neuron diseases. During his fellowship, he read over 300 muscle biopsies, and continues to interpret muscle biopsies as a faculty member. His weekly clinic specializes in Inclusion Body Myositis, and he serves as the director of the Muscular Dystrophy Association clinic and co-director of the Johns Hopkins Myositis Center. He has seen over 200 IBM patients who are enrolled into a large prospective clinical study on IBM, one of the largest such cohorts in the country. He was the site PI for the Novartis-sponsored clinical trial of Bimagrumab in sporadic Inclusion Body Myositis.
- MD: Baylor College of Medicine, Houston, TX
- PhD: Molecular and Cell Biology, Baylor College of Medicine
- Internship: Johns Hopkins Hospital
- Neurology Residency: Johns Hopkins Hospital
- Neuromuscular Fellowship: Johns Hopkins Hospital
Selected Recent Original Research Publications:
- Lloyd TE*, Mammen AL, Amato AA, Weiss MD, Needham M, Greenberg SA*. Evaluation and Construction of Diagnostic Criteria for Inclusion Body Myositis. 2014; 83:426-33.
- Roda RR, Schindler A, Blackstone C, Mammen AL, Corse AM, Lloyd TE. Laing Distal Myopathy Pathologically Resembling Inclusion Body Myositis. Annals of Clinical and Translational Neurology 2014:1053-8.
- Lloyd TE*, Christopher-Stine L*, Pinal-Fernandez I, Tiniakou E, Petri M, Baer A, Danoff S, Pak K, Casciola-Rosen L, Mammen AL. Cytosolic 5’-nucleotidase 1A is a common target of circulating autoantibodies in several autoimmune diseases. Arthritis Care Research 2015: doi: 10.1002/acr.22600.
- Mammen AL, Casciola-Rosen L, Christopher-Stine L, Lloyd TE and Wagner KR. Myositis specific autoantibodies are specific for myositis compared to genetic muscle disease. Neurology: Neuroimmunology & Neuroinflammation 2015 Nov 19;2(6):e172.
*Equal contribution
Selected Review:
Lloyd TE. Novel therapeutic approaches for inclusion body myositis. Current Opinion in Rheumatology. 2010; 22(6): 658-64.
